Alongside owning two Chicago-based firms, Raven S. Cashaw is an agile coach at Northwestern Medicine, which she joined in August 2019. Raven S. Cashaw also supports several nonprofits, such as the American Diabetes Association (ADA), which aims to reduce the number of people diagnosed with the disease every year.
ADA, which also advocates on behalf of people with diabetes, has applauded a decision by the U.S. Food and Drug Administration to reclassify insulin as a biologic. The move, which the group has repeatedly called for, could lay the foundation for making insulin cheaper for patients, according to the organization.
ADA notes that the reclassification could allow for biosimilar and interchangeable insulins to be created at a lower cost, which could drive down prices. The nonprofit also highlights that many sufferers cannot afford to take insulin regularly, despite it being a life-sustaining medication.
Though ADA claims that the struggle to reduce the cost of insulin is not over, the reclassification is seen as an important milestone.
ADA, which also advocates on behalf of people with diabetes, has applauded a decision by the U.S. Food and Drug Administration to reclassify insulin as a biologic. The move, which the group has repeatedly called for, could lay the foundation for making insulin cheaper for patients, according to the organization.
ADA notes that the reclassification could allow for biosimilar and interchangeable insulins to be created at a lower cost, which could drive down prices. The nonprofit also highlights that many sufferers cannot afford to take insulin regularly, despite it being a life-sustaining medication.
Though ADA claims that the struggle to reduce the cost of insulin is not over, the reclassification is seen as an important milestone.
